Menu

Interferon Discoverer Dies

Jean Lindemann, the virologist who helped figure out that interferons were responsible for anti-viral responses, has passed away at age 90.

Jan 26, 2015
Kerry Grens

WIKIMEDIA, MRC NATIONAL INSTITUTE FOR MEDICAL RESEARCHJean Lindenmann, the virologist who, along with Alick Isaacs at the National Institute for Medical Research in London, helped identify interferons for the first time passed away earlier this month (January 15). He was 90.

Lindenmann was a postdoc in the 1950s when he and Isaacs discovered that interferons were responsible for blocking future infections after chicken egg membranes had been exposed to an inactivated form of the virus.

According to The New York Times (NYT), “[a]fter his discovery, Dr. Lindenmann returned to his original institution, the University of Zurich, saying he wanted to leave further study of interferons to others.” Lindenmann sought an answer to a phenomenon in laboratory mice that some were resistant to influenza and others not. “The answer turned out to be interferon again,” according to the NYT.

In 1987, upon the 30th anniversary of the discovery of interferon, the Journal of Interferon published a special issue devoted to Lindenmann. Then editor-in-chief Charles Weismann wrote: “Not many scientists have the satisfaction of laying the foundations for a new field of research, and not only living to see its successful evolution but also contributing significantly, time and again, to its development.”

Lindenmann is survived by two sons and four grandchildren.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.